Programme 2022

Programme of the 6th AMR Conference

Conference Day 1
Thursday, 7 April 2022

Conference Day 2
Friday, 8 April 2022

Conference Day 1

Thursday, 7 April 2022

09:00 – 11:00

Pre-conference Meeting

BEAM Alliance General Assembly

// for BEAM members only //

11:00 – 11:30

Networking Break

11:30 – 13:00

Pre-conference workshops & site meetings

Workshop with a Focus on drug development by Novo Repair Impact Fund

  1. Introduction, by Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria
  2. Putting the puzzle pieces together by Enza Di Modugno, Global Head Infectious Disease and Immunology, Pharma Partnering, F. Hoffmann-La-Roche Ltd, Basel, Switzerland
  3. Chemistry, production, stability by Aleksandar Danilovsky, Chief Scientific Officer (CSO), Xellia Pharmaceuticals, Copenhagen, Denmark
  4. Discussion

Networking event by AntiResist (by invitation only) 

13:00 – 21:30

Registration, poster presentations and exhibition open

13:00 – 14:00

Lunch Break

14:00 – 15:30

Opening | Keynote | Plenary talk

AMR innovation: Finally on track to market & patients?

Intro talks by:

  • Marc Gitzinger, Vice-Président, BEAM Alliance & CEO Bioversys
  • Martin Heidecker, AMR Action Fund
  • Aleksandra Opalska, European Commission

Moderator:

  • Marc Gitzinger, Vice-Président, BEAM Alliance & CEO Bioversys

Speakers:

  • Erin Duffy, CARB-X
  • William Stubbings, Roche
  • Valeria Gigante, WHO
  • Bruce Altevogt, EFPIA

15:30 – 16:00

Coffee Break with poster session & exhibition

15:30 – 20:30

1-to-1 Partnering Meetings

16:00 – 17:30

Parallel Tracks

A new era for TB drug development: From innovation trial design to efficient drug regiments

Moderator:

  • Michel Pieren, BioVersys

Speakers:

  • Andreas Diacon, TASK
  • Michael Hoelscher, University of Munich
  • David Barros-Aguirre, GSK


Hosted by the IMI AMR Accelerator & in cooperation with the Unite4TB/Era4TB consortia

Diagnostics in AMR: Focus on market needs & learnings from COVID-19 innovations

Moderator:

  • Till Bachmann, University of Edinburgh

Speakers:

  • Stefanie Deinhard-Emmer, University Clinic of Jena
  • Jessica Caffrey, QuantumDx
  • Cecilia Ferreyra, FIND

Impact of pull incentives on the R&D portfolio: Current status & perspectives

Moderator:

  • Kevin Outterson, Professor of Law & N. Neal Pike Scholar in Health and Disability Law, Boston University & Executive Director, CARB-X

Speakers:

  • Lesley Ogilvie, Global AMR R&D Hub
  • Colm Leonard, NICE
  • Peter Beyer, WHO
  • Jean-Baptiste Perrin, European Commission
  • David Ridley, Duke Margolis

17:30 – 18:00

Coffee Break with poster session & exhibition

18:00 – 19:30

Start-up pitching session

Start-up pitches @AMR Conference

Start-up pitches and input for investors & funders

hosted by INCATE

Prize Sponsor:

19:30 – 21:30

Joint reception & Dinner in the exhibition hall

Conference Day 2

Friday, 8 April 2022

08:00 – 18:30

Registration, poster presentations and exhibition open

08:30 – 10:00

Parallel Tracks

Animal infection models & other tools for preclinical efficacy

Moderator:

  • Peter Jackson, INFEX Therapeutics

Speakers:

  • Jennifer Hoover, GSK
  • Glenn Dale, BioVersys
  • Erin Duffy, CARB-X
  • Robin Duman, Vibiosphen

in cooperation with IMI AMR Accelerator & further partners

Novel Technologies to combat AMR (AI, phages, imaging, metabolomics, microfluids)

Moderator:

  • Christoph Dehio, NCCR AntiResist

Speakers:

  • Jon Stokes, PhareBio
  • Martin Loessner, ETH Zurich
  • Knut Drescher, Uni Basel
  • Mattia Zampieri, ETH ZUrich
  • Sundar Hengoju, Leibniz HKI

in cooperation with the NCCR AntiResist network

Focus on One Health

Moderator:

  • Lesley Ogilvie, Global AMR R&D Hub

Speakers:

  • Tine Rikke Jorgenson, WHO
  • Jomana Musmar,  PACCARB
  • Ghada Zoubiane, ICARS
  • Amit Khurana, CSE

hosted by the Global AMR R&D Hub

10:00 – 10:45

Coffee Break with poster session & exhibition

10:00 – 16:30

1-to-1 Partnering Meetings

10:45 – 12:00

Plenary Session

From One Health to Sustainable Development Goals: Why there is no option than to fight AMR on a global scale

Moderator:

  • Peter Beyer, WHO

Speakers:

  • Louise Norton-Smith, Department of Health & Social Care, UK
  • Jomana Musmar, PACCARB, US government
  • Jean-Pierre Paccaud , GARDP
  • Emma Hannay, FIND

12:00 – 13:30

Lunch Break with poster session & exhibition

and 

UK Government hosted lunch reception with HMA Jane Owen
Due to unforeseen circumstances, Dame Sally Davies, UK Special Envoy on AMR will not be attending the AMR Conference in Basel.
Her Majesty’s Ambassador to Switzerland, Jane Owen will be attending on behalf of the UK Government.

13:30 – 14:30

Parallel Tracks

Focus on clinical development/trials & regulatory perspectives

Moderator:

  • Florence Séjourné, Da Volterra

Speakers:

  • Marc Bonten, Utrecht University/ECRAID
  • Najy Alsayed, Menarini
  • Radu Botgros, EMA
  • William Stubbings, Roche

Vaccines back on track to combat AMR: New approaches & challenges

Moderator:

  • Bernhard Kerscher, PEI

Speakers:

  • Isabel Frost, WHO
  • Cristina Alaimo, LimmaTech Biologics AG
  • Juanjo Infante, VAXDYN

Diagnostic programmes

Moderator:

  • Till Bachmann, University of Edinburgh

Speakers:

  • Anita Suresh, FINDDx
  • Belinda Ngongo, Illumina
  • Christian Brandt, Nanozoo

in cooperation with

14:30 – 15:00

Networking Break

15:00 – 16:00

Parallel Tracks

Focus on clinical needs: Which innovation in AMR is in demand?

Moderator:

  • Valeria Gigante, WHO

Speakers:

  • Apostolos Armaganidis, Attikon University Hospital
  • Andreas Widmer, University Hospital Basel
  • Cecilia Ferreyra, FINDDx
in cooperation with WHO

Therapeutic programmes

Moderator:

  • Frédéric Peyrane, BEAM Alliance

Speakers:

  • Glenn Dale, BioVersys
  • Peter Jackson, Infex Therapeutics
  • Florence Séjourné, Da Volterra
  • Georges Gaudriault, Deinove
  • Cindy Fevre, Pherecydes

(company presentations)

Focus on fungal infections: Current trends & developments – (shared lessons learned for AMR?)  

Moderator:

  • Mark Jones, Basilea

Speakers:

  • Maja Weisser Rohacek, Uni Basel
  • Rienk Pypstra, Pfizer
  • Hatim Sati, WHO

16:00 – 16:30

Coffee Break with poster session & exhibition

16:30 – 17:30

Plenary session

Cooperation as new normal?
New cooperation models (PPPs, investors, Pharma/SMEs, public entities) – from early stage to clinical development

Moderator:

  • Marc Lemonnier, Antabio & BEAM Alliance

Speakers:

  • Erin Duffy, CARB-X
  • Sebastian Kreuz, Boehringer Ingelheim
  • Jürgen Popp, Leibniz Institute of Photonic Technology
  • Holger Zimmermann, AiCuris Incubator

17:30 – 18:30

Closing reception

BEAM Alliance programme committee

Marc Gitzinger

CEO, BioVersys AG & Vice President, BEAM Alliance

Marc Lemonnier

Founding CEO, Antabio SAS

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance